Business Context and Reporting Period
This Form 8-K reports on the results of the 2024 Annual Meeting of Stockholders held by Aptevo Therapeutics Inc. on June 7, 2024. The filing details the voting outcomes for four specific proposals presented to shareholders.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to corporate governance voting results.
Material Changes and Voting Results
Four proposals were voted upon at the Annual Meeting:
- Proposal 1 (Election of Directors): Both nominees, Daniel J. Abdun-Nabi and Grady Grant, III, were elected to the Board of Directors. However, a significant portion of votes were withheld (approximately 333,600 each) and broker non-votes were recorded (704,366 each).
- Proposal 2 (Ratification of Auditors): The appointment of Moss Adams LLP as the independent registered public accounting firm for 2024 was approved with 1,271,108 votes for, 232,874 against, and 4,477 abstentions.
- Proposal 3 (Stock Incentive Plan): The Second Amended and Restated 2018 Stock Incentive Plan was approved with 442,849 votes for, 355,401 against, and 5,843 abstentions. There were 704,366 broker non-votes.
- Proposal 4 (Executive Compensation): The non-binding advisory proposal regarding named executive officer compensation was approved with 436,765 votes for, 365,824 against, and 1,504 abstentions. There were 704,366 broker non-votes.
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, outlook, or specific risk factors. It strictly reports the procedural outcomes of the shareholder vote.
Investor Verification Checklist
- Verify the high number of broker non-votes (704,366) on Proposals 1, 3, and 4, which may indicate significant passive holdings or specific broker voting policies.
- Review the substantial "Withheld" votes for the director elections (over 333,000 each) to understand shareholder sentiment regarding the board.
- Confirm the details of the approved Second Amended and Restated 2018 Stock Incentive Plan in the referenced Proxy Statement filed on April 23, 2024.
- Note that the approval of executive compensation was non-binding advisory.